The ligand-based virtual screening of an original chemical library, using atypical antipsychotics as query compounds led to the identification of a novel scaffold with inhibitory activity at the 5-HT 2A serotonin receptor. The hit compounds were confirmed by pharmacological evaluation at the 5-HT 2A receptor and complemented by the selection of other representatives of the same chemical family within our chemical library. A promising scaffold of 6-(pyperazin-1-yl) purine was identified, and the binding mode is illustrated with an automated docking exploration on a homology built model of the 5-HT 2A receptor. The present results constitute an excellent starting point for the discovery of new chemical entities with antipsychotic activity.Schizophrenia is a severe disorder that affects around 24 million people worldwide, typically beginning in late adolescence or early adulthood. It constitutes one of the major psychiatric disorders in the world, and it can impair functioning through the loss of the acquired capability of earning ones own livelihood or through the disruption of studies [1]. Up to date, pharmacological therapy with antipsychotics constitutes the most effective way to maintain most of the symptoms under control. Nowadays, clozapine, discovered nearly 50 years ago, remains as the gold standard antipsychotic, being the only licensed drug indicated for treatment-resistant schizophrenia. However, its use is restricted to these cases mainly due to the risk of agranulocytosis, its major adverse effect [2]. Based on its high affinity at the serotonin 5-HT 2A receptors, modulating its intermediate affinity over dopamine D 2 receptor, a putative mechanism of action of the so-called atypical antipsychotic drugs has been primary established by the Meltzer index, which is the relationship between the affinities at the aforementioned receptors [3]. However, recent multirreceptorial profiling of clozapine has shown its affinity at several aminergic G protein-coupled receptors (GPCRs) [4], opening a new scenario where the beneficial effects of atypical antipsychotics on cognition, negative symptoms, and the low incidence of EPS are mediated by a complex blend of interactions. Therefore, there has been growing interest in the discovery of new compounds that exhibit a similar pharmacological profile as clozapine, but possessing clozapine-unrelated chemical structures.Three dimensional ligand-based virtual screening (3D-LBVS) represents a good strategy to retrieve original, chemically different compounds from a chemical database, displaying similar pharmacological profile to a given compound with clinical interest [5,6]. This statement is not in disagreement with the excellent performance of 2D-based LBVS methodologies, as it has been noted by several authors [6,7]. For the particular case of antipsychotics, however, 3D-LBVS appears as an especially well suited technique attending to the following reasons: i) The target proteins are several aminergic receptors of the GPCR superfamily. Even if the traditional h...